EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fibulin‐4 as a potential extracellular vesicle marker of fibrosis in patients with cirrhosis

Masaru Kumagai, Atsunori Tsuchiya iD, Yuan Yang, Nobutaka Takeda, Kazuki Natsui, Yui Natusi, Kei Tomiyoshi, Fusako Yamazaki, Yohei Koseki, Hiroki Shinchi, Naoko Imawaka, Ryo Ukekawa und 5 weitere

FEBS Open Bio · 2024

DOI: 10.1002/2211-5463.13842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2024. Verfasst von Masaru Kumagai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biomarkers, Extracellular Vesicles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was supported by a Grant-in-Aid for Scientific Research (B) (22H02866 and 22H03055) and a Grant-in-Aid for Challenging Research (Exploratory) (22….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic liver injury leads to decreased liver function and increased fibrosis. Fibrosis is not only associated with the development of portal hypertension and carcinogenesis, but with the occurrence of events and a poor prognosis, highlighting the importance of non‐invasive fibrosis assessment in patients. In the present study, we searched for markers related to liver fibrosis via proteomic analysis of small extracellular vesicles (sEVs). In the discovery cohort, proteomic analysis was carried out in the sEVs extracted from the sera of 5 patients with decompensated cirrhosis, 5 patients with compensated cirrhosis, and 5 controls without liver disease. Interestingly, in this cohort, fibulin‐4 was significantly associated with cirrhosis while in the validation cohort [formed by 191 patients: 7 patients without disease, 16 patients without liver disease (other diseases), 38 patients with chronic liver disease (CLD), 75 patients with cirrhosis of Child–Pugh class A (36 without hepatocellular carcinoma [HCC], 29 with HCC), and 65 patients with cirrhosis of Child–Pugh class B–C (39 without HCC, 26 with HCC)], fibulin‐4/CD9 levels increased with cirrhosis progression. Furthermore, the fibulin‐4/CD9 ratio was significantly higher in patients with varices. Immunostaining also revealed strong fibulin‐4 expression in cholangiocytes within the fibrous areas and mesothelial cells in liver tissue blood vessels. Taken together, our results suggest that fibulin‐4, essential for lysyl oxidase activation, might be a new liver fibrosis marker found in the sEVs of patients with cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisBiomarkersExtracellular VesiclesHumansMaleFemaleMiddle AgedExtracellular Matrix ProteinsProteomicsAgedAdult

Stichwörter der Autor:innen

CD9cirrhosisextracellular vesiclesfibulin‐4liver fibrosis

Substanzen

BiomarkersEFEMP2 protein, humanExtracellular Matrix Proteins

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan.
  • Future Medical Research Center for Exosome and Designer Cells (F-DEC), Niigata University, Japan.
  • Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, China.
  • Project for Realization of Personalized Cancer Medicine, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Biotechnology Center, R&D Marketing Operations, FUJIFILM Wako Pure Chemical Corporation, Amagasaki-shi, Japan.
  • Department of Pharmacology, Faculty of Medicine, Oita University, Yufu, Japan.

ORCID-Profile: Atsunori Tsuchiya, Shuji Terai

Förderung

  • This research was supported by a Grant-in-Aid for Scientific Research (B) (22H02866 and 22H03055) and a Grant-in-Aid for Challenging Research (Exploratory) (22…

Zitieren

APA

Kumagai, M., Tsuchiya, A., Yang, Y., Takeda, N., Natsui, K., Natusi, Y., Tomiyoshi, K., Yamazaki, F., Koseki, Y., Shinchi, H., Imawaka, N., Ukekawa, R., Nishibu, T., Abe, H., Sasaki, T., Ueda, K., & Terai, S. (2024). Fibulin‐4 as a potential extracellular vesicle marker of fibrosis in patients with cirrhosis. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13842

Vancouver

Kumagai M, Tsuchiya A, Yang Y, Takeda N, Natsui K, Natusi Y, et al. Fibulin‐4 as a potential extracellular vesicle marker of fibrosis in patients with cirrhosis. FEBS Open Bio. 2024. doi:10.1002/2211-5463.13842

BibTeX
@article{Kumagai2024,
  author = {Kumagai, Masaru and Tsuchiya, Atsunori and Yang, Yuan and Takeda, Nobutaka and Natsui, Kazuki and Natusi, Yui and Tomiyoshi, Kei and Yamazaki, Fusako and Koseki, Yohei and Shinchi, Hiroki and Imawaka, Naoko and Ukekawa, Ryo and Nishibu, Takahiro and Abe, Hiroyuki and Sasaki, Takako and Ueda, Koji and Terai, Shuji},
  title = {Fibulin‐4 as a potential extracellular vesicle marker of fibrosis in patients with cirrhosis},
  journal = {FEBS Open Bio},
  year = {2024},
  doi = {10.1002/2211-5463.13842}
}
Kostenlos starten →